Shiloh
Editor, Senior Moderator
Source: http://www.cidrap.umn.edu/news-perspective/2019/10/stewardship-resistance-scan-oct-03-2019
Stewardship / Resistance Scan for Oct 03, 2019
Rapid diagnostic test data; New antibiotic vs gram-neg pneumonia
Filed Under:
Antimicrobial Stewardship; Diagnostics
[h=3]Accelerate Diagnostics touts data on rapid diagnostic test[/h] Accelerate Diagnostics presented three studies today at IDWeek 2019 in Washington, DC, that show promising results for its rapid phenotypic susceptibility test, according to a company press release.
In the RAPIDS-GN randomized controlled trial, conducted at Mayo Clinic and the University of California, Los Angeles, investigators reported that the Accelerate PhenoTest BC kit, when compared with legacy testing methods in gram-negative bacteremia patients, shortened reporting time to first gram-negative antibiotic change a full 24 hours sooner than legacy methods (17.4 vs 42.1 hours) and reporting time to any antibiotic change 6 hours sooner (8.6 vs 14.9 hours).
In a single-center study conducted by researchers at the University of Arkansas for Medical Sciences, use of the Accelerate Pheno system was associated with a statistically significant decrease in time on broad-spectrum gram-positive antibiotics of 23.3 hours and a decrease in time on broad-spectrum gram-negative antibiotics of 38.4 hours. Hospital length of stay was also reduced.
Data from a study conducted at the University of Iowa Hospitals and Clinics showed that implementation of Accelerate Pheno paired with antimicrobial stewardship team review resulted in early optimization of antibiotic therapy, with the highest impact seen in patients with resistant gram-negative infections.
"We are thrilled to see these data, which demonstrate conclusively that the Accelerate PhenoTest BC kit positively impacts clinical outcomes across a diverse set of institutions and patient populations," said Romney Humphries, PhD, Chief Scientific Officer of Accelerate Diagnostics. "The studies show an improvement in antibiotic use, a necessary factor for lowering the risk of multidrug-resistant infections and in preserving the patient's vital functions, while also improving the hospital's bottom line by reducing patient length of stay."
Oct 3 Accelerate Diagnostics press release
[h=3]Data show promise for novel antibiotic against gram-negative pneumonia[/h] Data presented today at IDWeek by Shionogi & Co researchers reveal that its investigational drug cefiderocol, a novel siderophore cephalosporin that has shown activity against a broad range of gram-negative bacteria, was non-inferior to meropenem in patients who had hospital-acquired pneumonia caused by gram-negative bacteria.
In the study, 148 patients were randomized to receive cefiderocol and 150 to meropenem. Illnesses were typically severe; 60% required mechanical ventilation, and a third had previous treatment failure. Patients received high doses (2 grams) of the drugs every 8 hours.
All-cause mortality at 14 days was similar for cefiderocol (12.4%) versus merpoenem (11.6%), as was clinical cure (64.8% vs 66.7%), and microbiological eradication (47.6% vs 48.0%).
Tsutae "Den" Nagata, MD, Shionogi's chief medical officer, in a company news release, said the findings "provide meaningful evidence that cefiderocol has the potential to be an effective treatment option for severely ill hospitalized patients with pneumonia….Recently, several new antibiotics have been introduced to address some carbapenem-resistant infections, but they do not address all resistant Gram-negative pathogens. Clinicians are in urgent need of novel therapeutic approaches to overcome the multiple resistance mechanisms that make these strains so difficult to treat."
The researchers recorded no unexpected safety issues with the new drug.
Cefiderocol—a cephalosporin—has a novel method of penetrating the tough outer membrane of gram-negative bacteria, including multidrug-resistant strains. It has been fast-tracked for assessment by the US Food and Drug Administration, which has assigned an action date of Nov 14 to the drug. It showed promising results against complicated urinary tract infections in a study published last year.
Oct 3 IDWeek abstract
Oct 2 Shionogi news release
Oct 26, 2018, CIDRAP News story "Fast-tracked antibiotic shows promise in phase 2 trial"
Stewardship / Resistance Scan for Oct 03, 2019
Rapid diagnostic test data; New antibiotic vs gram-neg pneumonia
Filed Under:
Antimicrobial Stewardship; Diagnostics
[h=3]Accelerate Diagnostics touts data on rapid diagnostic test[/h] Accelerate Diagnostics presented three studies today at IDWeek 2019 in Washington, DC, that show promising results for its rapid phenotypic susceptibility test, according to a company press release.
In the RAPIDS-GN randomized controlled trial, conducted at Mayo Clinic and the University of California, Los Angeles, investigators reported that the Accelerate PhenoTest BC kit, when compared with legacy testing methods in gram-negative bacteremia patients, shortened reporting time to first gram-negative antibiotic change a full 24 hours sooner than legacy methods (17.4 vs 42.1 hours) and reporting time to any antibiotic change 6 hours sooner (8.6 vs 14.9 hours).
In a single-center study conducted by researchers at the University of Arkansas for Medical Sciences, use of the Accelerate Pheno system was associated with a statistically significant decrease in time on broad-spectrum gram-positive antibiotics of 23.3 hours and a decrease in time on broad-spectrum gram-negative antibiotics of 38.4 hours. Hospital length of stay was also reduced.
Data from a study conducted at the University of Iowa Hospitals and Clinics showed that implementation of Accelerate Pheno paired with antimicrobial stewardship team review resulted in early optimization of antibiotic therapy, with the highest impact seen in patients with resistant gram-negative infections.
"We are thrilled to see these data, which demonstrate conclusively that the Accelerate PhenoTest BC kit positively impacts clinical outcomes across a diverse set of institutions and patient populations," said Romney Humphries, PhD, Chief Scientific Officer of Accelerate Diagnostics. "The studies show an improvement in antibiotic use, a necessary factor for lowering the risk of multidrug-resistant infections and in preserving the patient's vital functions, while also improving the hospital's bottom line by reducing patient length of stay."
Oct 3 Accelerate Diagnostics press release
[h=3]Data show promise for novel antibiotic against gram-negative pneumonia[/h] Data presented today at IDWeek by Shionogi & Co researchers reveal that its investigational drug cefiderocol, a novel siderophore cephalosporin that has shown activity against a broad range of gram-negative bacteria, was non-inferior to meropenem in patients who had hospital-acquired pneumonia caused by gram-negative bacteria.
In the study, 148 patients were randomized to receive cefiderocol and 150 to meropenem. Illnesses were typically severe; 60% required mechanical ventilation, and a third had previous treatment failure. Patients received high doses (2 grams) of the drugs every 8 hours.
All-cause mortality at 14 days was similar for cefiderocol (12.4%) versus merpoenem (11.6%), as was clinical cure (64.8% vs 66.7%), and microbiological eradication (47.6% vs 48.0%).
Tsutae "Den" Nagata, MD, Shionogi's chief medical officer, in a company news release, said the findings "provide meaningful evidence that cefiderocol has the potential to be an effective treatment option for severely ill hospitalized patients with pneumonia….Recently, several new antibiotics have been introduced to address some carbapenem-resistant infections, but they do not address all resistant Gram-negative pathogens. Clinicians are in urgent need of novel therapeutic approaches to overcome the multiple resistance mechanisms that make these strains so difficult to treat."
The researchers recorded no unexpected safety issues with the new drug.
Cefiderocol—a cephalosporin—has a novel method of penetrating the tough outer membrane of gram-negative bacteria, including multidrug-resistant strains. It has been fast-tracked for assessment by the US Food and Drug Administration, which has assigned an action date of Nov 14 to the drug. It showed promising results against complicated urinary tract infections in a study published last year.
Oct 3 IDWeek abstract
Oct 2 Shionogi news release
Oct 26, 2018, CIDRAP News story "Fast-tracked antibiotic shows promise in phase 2 trial"